Key Horizon drug Tepezza has hearing loss warning added to labeling
peakSTOCK/iStock via Getty Images

The US FDA has added a warning about the potential for severe hearing impairment including hearing loss associated with Horizon Therapeutics' (NASDAQ:HZNP) Tepezza (teprotumumab). Horizon fell 2.7% amid the news on Thursday.
The therapy is indicated for thyroid eye disease.
The new labeling indicates that hearing loss could be permanent. It adds that patients' hearing should be tested before, during, and after Tepezza treatment.

Tepezza is Horizon's best-selling drug and earned $405.3M in Q1 2023.
The therapy was instrumental in Amgen's (AMGN) decision in December to acquire Horizon (HZNP) for ~$28B.

More on Horizon Therapeutics

Amgen, FTC said there are no ongoing talks, though open to settlement over Horizon
FTC Surprise Challenge Of Amgen's Acquisition Of Horizon Therapeutics
Amgen: Questioning The Horizon Therapeutics Acquisition